Regeneration

Fifty-nine schools will break ground on projects to help nature, seeded by WWF-Canada's Go Wild Grants

Retrieved on: 
Monday, February 26, 2024
Indigenous, Regeneration, Bird, Climate, Plant, Nature, Biodiversity, Learning, Glencoe District High School, Water quality, History, Tree, Creativity, Student, John Abbott College, WWF-Canada, Forestry

Valued at $1,500 – $2,000, the grants will support student activities that help to protect or restore nature in schoolyards, campuses and communities.

Key Points: 
  • Valued at $1,500 – $2,000, the grants will support student activities that help to protect or restore nature in schoolyards, campuses and communities.
  • Since 2015, WWF-Canada has funded 529 Go Wild school and campus projects, awarding a total of $412,460.
  • Go Wild Grants help school communities learn about their local ecosystems, including their history and biodiversity, how they work, and what they need to thrive.
  • Elizabeth Hendriks, vice-president of restoration and regeneration at WWF-Canada, says:
    "We're delighted to be funding 59 new Go Wild projects.

MEMS in the Global Medical Market: New Report with 2020-2023 Data, CAGR Projections to 2028 and Profiles of Leading Players TE Connectivity, STMicroelectronics, Teledyne Dalsa and Silex Microsystems

Retrieved on: 
Thursday, February 22, 2024
MEMS, Ophthalmology, Regeneration, Drug, DDS, Toxicity, USD, Pressure, Silicon, Intelligence, Permeability, Temperature, Immunology, Cardiology, Honeywell, Growth, Polymer, Teledyne DALSA, ESG, Endocrinology, TE Connectivity, STMicroelectronics, Administration, Glass, Metal, Microelectromechanical systems, Route of administration, Solubility, Proteomics, LOC, Genomics, Diagnosis, Research, Biochemistry

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.
  • Of these, microfluidic and LOC devices account for the largest segment of the MEMS device market.
  • In terms of microfluidic devices, the key potential lies in developing cartridges that are highly sensitive, multichannel and multiplexing systems.
  • Competitive intelligence related to leading companies, their global rankings, recent developments, key financials and segmental revenues, and product portfolios
    Profiles of the leading market players, including TE Connectivity, Honeywell International Inc., STMicroelectronics, Teledyne Dalsa, and Silex Microsystems

Shamir Medical Center Reveals New Long-Term Results from Long COVID Study to Highlight Positive Impact on Symptoms Resulting from Hyperbaric Oxygen Therapy

Retrieved on: 
Thursday, February 15, 2024
Regeneration, Metabolism, Research, Randomized controlled trial, Tel Aviv University, Inflammation, Hyperbaric medicine, Quality of life, Neuron, Sleep, Psychiatry, Thrombosis, Shamir Medical Center, Cytokine, Fatigue, COVID, Patient, Gene, HBOT, Tissue, Pressure, Pharmaceutical industry

In a previous randomized controlled trial, significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long COVID patients who underwent a unique protocol of hyperbaric oxygen therapy were documented.

Key Points: 
  • In a previous randomized controlled trial, significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long COVID patients who underwent a unique protocol of hyperbaric oxygen therapy were documented.
  • This longitudinal follow-up included 31 patients from the original study, who were treated with 40 daily sessions of HBOT.
  • The results indicate HBOT can improve the quality of life, quality of sleep, psychiatric and pain symptoms of patients suffering from long COVID.
  • By delivering high oxygen concentrations, HBOT can enhance oxygen delivery to tissues, resulting in recovery of injured tissues permanent improvement.

CollPlant Issues Letter to Shareholders

Retrieved on: 
Thursday, February 15, 2024
Therapy, United Nations Global Compact, CLGN, Cancer, Ulcerative colitis, Regeneration, Regenerative medicine, Inflammatory Bowel Diseases, Breast augmentation, Polymerization, 3D, Patent, Social, AbbVie, Connective tissue, Drug discovery, ESG, Letter, 3D bioprinting, Epidermis, Breast, Genetic engineering, Safety, UC, Stratasys, Hyaluronic acid, Ecosystem, Patient, Medicine, Environment, Tissue

Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.

Key Points: 
  • Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.
  • In June of last year, we announced the achievement of an important milestone under this collaboration which triggered a $10 million payment from AbbVie to CollPlant.
  • Per CollPlant's agreement with AbbVie, CollPlant has the potential to receive additional milestones and option products payments, as well as receive meaningful royalties on product sales.
  • In the second quarter of 2023, CollPlant hired a dedicated expert to lead our Environment, Social and Governance (ESG) effort.

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Retrieved on: 
Wednesday, February 14, 2024
Engineering, Regeneration, Regenerative medicine, Inflammation, North Carolina State University, Neovascularization, Infection, South Korea, WBC, Wilson College, Tissue engineering, KSBM, Decellularization, Congress, CELU, Trauma, Tissue, Development, Culture of Korea, LSC, Wound healing

FLORHAM PARK, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its abstract “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells” has been accepted as a poster presentation at WBC 2024, the 12th World Biomaterials Congress which will be held on 26-31 May 2024 in Daegu, Republic of Korea, and hosted by the Korean Society for Biomaterials (KSBM). The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”

Key Points: 
  • The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”
    The study described in the poster presentation investigated Celularity’s tri-layer decellularized, dehydrated human amniotic membrane technology product as a carrier of induced pluripotent stem cell derived-limbal stem cells (iPSC-LSC) which were investigated for the treatment of limbal stem cell deficiency (LSCD).
  • Limbal Stem Cell (LSC) transplant is a recognized method to restore the ocular surface in advanced stem cell deficient corneas.
  • Its Tissue Engineering Lab Team is particularly interested in corneal tissue engineering, focusing primarily on ocular surface regeneration.
  • The off-the-shelf availability of existing commercial tri-layer decellularized, dehydrated human amniotic membrane products, in combination with iPSC-LSCs, may improve patient access to LSCD treatment and the therapeutic management of LSCD.

TimeProvider® 4500 Series is the Industry’s First Grandmaster to Provide High-Speed Network Interfaces up to 25 Gbps

Retrieved on: 
Wednesday, February 14, 2024
Regeneration, GNSS, Investment, Transport, Data-rate units, Integrated circuit, 5G, Precision Time Protocol, GUI, PTP, GPS, Satellite navigation, QZSS, Microchip Technology, FCAPS, MCHP, GALILEO, Security, Video game

Depending on the specific sites, the grandmaster could serve very few or a large number of gNodeB base stations.

Key Points: 
  • Depending on the specific sites, the grandmaster could serve very few or a large number of gNodeB base stations.
  • The TimeProvider 4500 grandmaster offers the flexibility to connect to various generations of network elements, which helps to preserve operators’ infrastructure investments.
  • The TimeProvider 4500 clock is the first 1588 grandmaster with 25 Gbps support.
  • A customer can connect the TimeProvider 4500 clock to various network devices using a choice of 1 Gbps, 10 Gbps or 25 Gbps network links.

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Retrieved on: 
Tuesday, February 13, 2024
JDRF, Diabetes, Biotechnology, Regeneration, Doctor of Philosophy, IST, MD, Escape Room, Research, Behavior informatics, CD47, Cell, NHP, Organoid, Safety, Transplant, Immunosuppression, Cell Stem Cell, Patient, Insulin, HIP, T1D, Glucose, Pharmaceutical industry

SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.” The paper evaluated a transplant of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells into a fully immunocompetent, diabetic non-human primate (NHP). These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets). The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.

Key Points: 
  • These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets).
  • The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.
  • This publication, along with the ongoing IST, will provide invaluable insights toward our stem cell derived product candidate, SC451.
  • It was thus demonstrated that the tightly controlled blood glucose levels and insulin independence was entirely due to well-functioning HIP p-islets.

CALLING ALL TRAVELERS: LAS TORRES PATAGONIA ANNOUNCES "10 VOLUNTEERS FOR 10 DAYS" ALL-EXPENSE PAID TRIPS TO HELP REBUILD PATAGONIAN HIKING TRAIL

Retrieved on: 
Tuesday, February 13, 2024
UNESCO, Survival, Social media, Regeneration, Longevity, Eighth Wonder, Volunteering, International, Tourism

PATAGONIA, Chile, Feb. 13, 2024 /PRNewswire/ -- Today, Las Torres Patagonia announces "10 Volunteers for 10 Days," a social media campaign and contest that offers the chance to win an all-expense paid voluntourism trip to the Eighth Wonder of the World in Chile.

Key Points: 
  • Led by the Patagonian family-owned property in Torres del Paine National Park, ten travelers will win the chance to participate in a voluntourism trip to the world-renowned hiking destination.
  • PATAGONIA, Chile, Feb. 13, 2024 /PRNewswire/ -- Today, Las Torres Patagonia announces " 10 Volunteers for 10 Days ," a social media campaign and contest that offers the chance to win an all-expense paid voluntourism trip to the Eighth Wonder of the World in Chile.
  • "Las Torres Patagonia has a generational commitment to the regeneration and longevity of this beautiful Chilean region," said Josian Yaksic, CEO of Las Torres Patagonia.
  • "More than ever, it is prudent to acknowledge the changing landscape and take action for its survival.

SuperReturn Extends Relationship with BackBay Communications

Retrieved on: 
Tuesday, February 13, 2024
Professional Services, Asset Management, Other Communications, Digital Marketing, Data Analytics, Public Relations, Investor Relations, Marketing, Advertising, Communications, Content Marketing, Finance, Consulting, Regeneration, Grimaldi Forum, Investment, News, Growth, Drawdown, PR, Mahim, LP record, GP, Partnership

SuperReturn, the world’s leading private equity and venture capital conference series, has again selected BackBay Communications, an award-winning financial services public relations agency, as its PR and media relations partner for the upcoming SuperReturn International, SuperInvestor, SuperReturn North America and SuperReturn Private Credit US conferences, taking place June 4-7, November 5-8, and November 11-12, in Berlin, Monaco, and New York, respectively.

Key Points: 
  • SuperReturn, the world’s leading private equity and venture capital conference series, has again selected BackBay Communications, an award-winning financial services public relations agency, as its PR and media relations partner for the upcoming SuperReturn International, SuperInvestor, SuperReturn North America and SuperReturn Private Credit US conferences, taking place June 4-7, November 5-8, and November 11-12, in Berlin, Monaco, and New York, respectively.
  • SuperReturn has also engaged BackBay as PR partner for SuperReturn Private Credit Europe on March 11-12 in London.
  • At SuperReturn Private Credit Europe and US, thought leaders will discuss fundraising, credit secondaries, niche and specialty finance, real estate debt and more.
  • For more information on SuperReturn Private Credit Europe, visit https://informaconnect.com/superreturn-private-credit-europe/
    For SuperReturn Private Credit US, visit https://informaconnect.com/superreturn-private-credit/

Global Tissue Engineering Research Analysis Report 2023: Market to Reach $8.9 Billion by 2028, Driven by Rising Funding and Investments and Advancements in Regenerative Medicines - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Manufacturing, Other Health, Stem Cells, Pharmaceutical, Medical Devices, Hospitals, Genetics, Cardiology, Science, Biotechnology, Other Science, Health, Engineering, Research, Medical Supplies, Government of India, Scaffolding, Investment, Growth, Accident, B cell, Collagen, Trauma, Orthopedic surgery, Regeneration, Biology, Tissue engineering, Inspiration, DST, 3D bioprinting, Market development, USD, Pharmaceutical industry

The global tissue engineering market is projected to reach USD 8.9 billion by 2028 from an estimated USD 4.4 billion in 2023, at a CAGR of 15.3%

Key Points: 
  • The global tissue engineering market is projected to reach USD 8.9 billion by 2028 from an estimated USD 4.4 billion in 2023, at a CAGR of 15.3%
    The growth of this market can be attributed to rising funding and investments for the development of advanced tissue engineering solutions and growing technological advancements in regenerative medicines.
  • The synthetic material segment accounted for the largest share of material in the global tissue engineering market in 2022.
  • The increasing advancements in cell therapies and regenerative medicines are promoting the growth of the tissue engineering market in the region.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue engineering market.